RATIONALE: Dysregulated neutrophil functions with age and sepsis are described. Statins are associated with improved infection survival in some observational studies, but trials in critically ill patients have not shown benefit. Statins also alter neutrophil responses in vitro. OBJECTIVES: To assess neutrophil migratory accuracy with age during respiratory infections and determine if and how a statin intervention could alter these blunted responses. METHODS: The migratory accuracy of blood neutrophils from young (aged <35 yr) and old (aged >60 yr) patients in health and during a lower respiratory tract infection, community-acquired pneumonia, and pneumonia associated with sepsis was assessed with and without simvastatin. In vitro results were confirmed in a double-blind randomized clinical trial in healthy elders. Cell adhesion markers were assessed. MEASUREMENTS AND MAIN RESULTS: In vitro neutrophil migratory accuracy in the elderly deteriorated as the severity of the infectious pulmonary insult increased, without recovery at 6 weeks. Simvastatin rescued neutrophil migration with age and during mild to moderate infection, at high dose in older adults, but not during more severe sepsis. Confirming in vitro results, high-dose (80-mg) simvastatin improved neutrophil migratory accuracy without impeding other neutrophil functions in a double-blind randomized clinical trial in healthy elders. Simvastatin modified surface adhesion molecule expression and activity, facilitating accurate migration in the elderly. CONCLUSIONS: Infections in older adults are associated with prolonged, impaired neutrophil migration, potentially contributing to poor outcomes. Statins improve neutrophil migration in vivo in health and in vitro in milder infective events, but not in severe sepsis, supporting their potential utility as an early intervention during pulmonary infections. Clinical trial registered with www.clinicaltrialsregister.eu (2011-002082-38).
RATIONALE: Dysregulated neutrophil functions with age and sepsis are described. Statins are associated with improved infection survival in some observational studies, but trials in critically ill patients have not shown benefit. Statins also alter neutrophil responses in vitro. OBJECTIVES: To assess neutrophil migratory accuracy with age during respiratory infections and determine if and how a statin intervention could alter these blunted responses. METHODS: The migratory accuracy of blood neutrophils from young (aged <35 yr) and old (aged >60 yr) patients in health and during a lower respiratory tract infection, community-acquired pneumonia, and pneumonia associated with sepsis was assessed with and without simvastatin. In vitro results were confirmed in a double-blind randomized clinical trial in healthy elders. Cell adhesion markers were assessed. MEASUREMENTS AND MAIN RESULTS: In vitro neutrophil migratory accuracy in the elderly deteriorated as the severity of the infectious pulmonary insult increased, without recovery at 6 weeks. Simvastatin rescued neutrophil migration with age and during mild to moderate infection, at high dose in older adults, but not during more severe sepsis. Confirming in vitro results, high-dose (80-mg) simvastatin improved neutrophil migratory accuracy without impeding other neutrophil functions in a double-blind randomized clinical trial in healthy elders. Simvastatin modified surface adhesion molecule expression and activity, facilitating accurate migration in the elderly. CONCLUSIONS: Infections in older adults are associated with prolonged, impaired neutrophil migration, potentially contributing to poor outcomes. Statins improve neutrophil migration in vivo in health and in vitro in milder infective events, but not in severe sepsis, supporting their potential utility as an early intervention during pulmonary infections. Clinical trial registered with www.clinicaltrialsregister.eu (2011-002082-38).
Authors: Sachin Kumar; Juying Xu; Charles Perkins; Fukun Guo; Scott Snapper; Fred D Finkelman; Yi Zheng; Marie-Dominique Filippi Journal: Blood Date: 2012-08-29 Impact factor: 22.113
Authors: T A Kelly; D D Jeanfavre; D W McNeil; J R Woska; P L Reilly; E A Mainolfi; K M Kishimoto; G H Nabozny; R Zinter; B J Bormann; R Rothlein Journal: J Immunol Date: 1999-11-15 Impact factor: 5.422
Authors: Sandra Mara A Arraes; Marta S Freitas; Simone V da Silva; Heitor A de Paula Neto; Jose Carlos Alves-Filho; Maria Auxiliadora Martins; Anibal Basile-Filho; Beatriz M Tavares-Murta; Christina Barja-Fidalgo; Fernando Q Cunha Journal: Blood Date: 2006-07-18 Impact factor: 22.113
Authors: M Chello; P Mastroroberto; G Patti; A D'Ambrosio; M Cortez Morichetti; G Di Sciascio; E Covino Journal: Heart Date: 2003-05 Impact factor: 5.994
Authors: R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno Journal: Intensive Care Med Date: 2013-01-30 Impact factor: 17.440
Authors: Pallavi Bedi; Donald J Davidson; Brian J McHugh; Adriano G Rossi; Adam T Hill Journal: Am J Respir Crit Care Med Date: 2018-10-01 Impact factor: 21.405
Authors: Shaunna R Simmons; Manmeet Bhalla; Sydney E Herring; Essi Y I Tchalla; Elsa N Bou Ghanem Journal: Infect Immun Date: 2021-03-17 Impact factor: 3.441
Authors: Kylie B R Belchamber; Onn S Thein; Jon Hazeldine; Frances S Grudzinska; Aduragbemi A Faniyi; Michael J Hughes; Alice E Jasper; Kay Por Yip; Louise E Crowley; Sebastian T Lugg; Elizabeth Sapey; Dhruv Parekh; David R Thickett; Aaron Scott Journal: Cells Date: 2022-09-16 Impact factor: 7.666
Authors: Caroline M Weight; Simon P Jochems; Hugh Adler; Daniela M Ferreira; Jeremy S Brown; Robert S Heyderman Journal: Front Cell Infect Microbiol Date: 2021-05-25 Impact factor: 5.293